Dec 6 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

Vertex delivered a split result this morning that left investors parsing mixed signals. The tax technology provider beat on EPS but missed revenue expectations. Shares were down nearly 10% by the ...

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

Add Yahoo as a preferred source to see more of our stories on Google. Renowned SFX and makeup artist Gi Ponci recently posted a picture of an official Avengers: Doomsday merch that featured as many as ...

Renowned SFX and makeup artist Gi Ponci recently posted a picture of an official Avengers: Doomsday merch that featured as many as 28 confirmed characters from the film. The image not only served as a ...

Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Vertex Pharmaceuticals’VRTX-1.22%decrease; red down pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...